Ann: Positive Preliminary Results from SMARTCOUGH-C-2 Study, page-287

The tech will never replace a medical professional, it will help them...

ResAppDx achieved a positive percent agreement (PPA) between 73% and 78% and a negative percent agreement (NPA) between 71% and 86% when compared to a clinical diagnosis for lower respiratory tract disease, asthma/reactive airway disease (for children over 2 years of age) and primary upper respiratory tract disease. ResApp intends to submit a de novo premarket submission to the United States Food and Drug Administration (FDA) for approval in these three indications.